Aspira is now Offering Treatment for Patients with COVID: Bebtelovimab

  • This is a monoclonal antibody used to treat patients with COVID.
  • It is given as a slow IV injection over 30 seconds.  Then we monitor patients for 1 hour to ensure there is no reaction.
  • This medication is for anyone ≥12 years of age and weighing at least 40 kg.
  • The dosage is bebtelovimab 175 mg administered as a single intravenous injection over at least 30 seconds.
  • Administration of bebtelovimab is recommended to occur as soon as possible after positive results of direct SARS-CoV-2 viral testing and within 7 days of symptom onset.
  • This medication is best for patients who are at high risk for progression to severe COVID-19, including hospitalization or death, and
  • for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate.

 

From the FDA

Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for a new monoclonal antibody for the treatment of COVID-19 that retains activity against the omicron variant. The EUA for bebtelovimab is for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kilograms, which is about 88 pounds) with a positive COVID-19 test, and who are at high risk for progression to severe COVID-19, including hospitalization or death, and for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.

Bebtelovimab is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19. Treatment with bebtelovimab has not been studied in patients hospitalized due to COVID-19. Monoclonal antibodies, such as bebtelovimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation.

 

FDA Fact Sheet> 

To get Bebtelovimab:

Contact us via text at 302-517-1385 and we can make arrangements for you to come into to get the treatment.  You can also email us at info@aspirahealth.net to arrange an injection.

0 New comments

Leave a Reply

Your email address will not be published.

Latest News and Clinic Information

We are your partner in health. Stay up to date with latest news and information.

Evusheld Monoclonal Antibody Treatment Now Available

Aspira Health has been authorized to give the monoclonal antibody; Evusheld.  Learn more about Evusheld in this article. Schedule an appointment with Aspira Health to learn more about getting a prescription for the monoclonal antibody; Evusheld.

Read More

Premier Telehealth Coming to Southern Delaware 4/1

As a premier healthcare provider in Southern Delaware, Aspira Health is releasing a mobile app  that will include a suite of robust telemedicine features to enrich and enhance patients’ access to healthcare. The new mobile application builds upon Aspira Health’s commitment towards integrating their exceptional care with more modern and innovative solutions for the local community.
Read More

Treatment for Patients with Covid

Monoclonals for COVID Treatment – Now Available at Aspira

Read More